A hysteroscopic fluid management system includes a saline source with an electrolyte concentration, at least one pressure mechanism for circulating saline to and from a targeted site and through a filter having filter characteristics back to the source, and a controller. The controller provides a saline inflow in a first flow path to the site and a saline outflow in a second flow path from the site through the filter and back to the source at a controlled flow rate. A diagnostic or therapeutic procedure is performed at the site in the presence of the saline. The filter characteristics and the controlled flow rate are selected to (1) cause substantially no change in the electrolyte concentration in the saline, (2) to prevent hemolysis of greater than 5% of filtered red blood cells exposed to the saline, and/or (3) to minimize effect on prothrombin time of plasma exposed to the filter.

The invention provides apheresis devices and their use for removal of substantially all types of cell free DNA (cfDNA) in patients’ blood, including nucleosome-bound cfDNA, exosome-bound cfDNA and unbound cfDNA (including double stranded DNA (dsDNA), single stranded DNA (ssDNA) and oligonucleotides), to limit the negative effects of the circulating cfDNA and to treat various diseases.

A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

A filter apparatus for removing small molecule chemotherapy agents from blood is provided. The filter apparatus comprises a housing with an extraction media comprised of polymer coated carbon cores. Also provided are methods of treating a subject with cancer of an organ or region comprising administering a chemotherapeutic agent to the organ or region, collecting blood laded with chemotherapeutic agent from the isolated organ, filtering the blood laden with chemotherapeutic agent to reduce the chemotherapeutic agent in the blood and returning the blood to the subject.

A blood filter device having an iron-chelating molecule, a haem-binding molecule and a haemoglobin-binding molecule bound to a support. Use of the device in a vessel containing blood, for example a blood bag or a flow line, removes haemolysis-derived components from the blood.

Described are embodiments that include methods and devices for separating composite liquids into components. Embodiments involve the use of a flexible membrane for separating a composite liquid into components. The composite liquid may include, in embodiments, a cellular containing liquid, such as whole blood or components of whole blood. In one specific embodiment, the composite liquid is a buffy coat.

A renal failure therapy system having an electrically floating fluid pathway is disclosed. The example system includes a dialyzer, a blood circuit in fluid communication with the dialyzer, and a dialysis fluid circuit in fluid communication with the dialyzer. The system also includes an electrically floating fluid pathway comprising at least a portion of the blood circuit and at least a portion of the dialysis fluid circuit. The only electrical path to ground is via used dialysis fluid traveling through the renal failure therapy system to earth ground. The disclosed system enables at least one electrical component in the at least a portion of the dialysis fluid circuit of the electrically floating fluid pathway to be electrically bypassed.

A renal failure therapy system having an electrically floating fluid pathway is disclosed. The example system includes a dialyzer, a blood circuit in fluid communication with the dialyzer, and a dialysis fluid circuit in fluid communication with the dialyzer. The system also includes an electrically floating fluid pathway comprising at least a portion of the blood circuit and at least a portion of the dialysis fluid circuit. The only electrical path to ground is via used dialysis fluid traveling through the renal failure therapy system to earth ground. The disclosed system enables at least one electrical component in the at least a portion of the dialysis fluid circuit of the electrically floating fluid pathway to be electrically bypassed.

A blood purification apparatus that is capable of, with no preparatory operations, performing substitution by supplying dialysate in a dialysate introduction line to a blood circuit during ultrafiltration treatment, or performing blood return by immediately supplying the dialysate in the dialysate introduction line to the blood circuit after the ultrafiltration treatment. A blood purification apparatus includes a dialyzer, a dialysate introduction line, a dialysate drain line L2 through which drain liquid from the dialyzer is drained, and an ultrafiltration pump capable of removing water from the blood in the blood circuit. The blood purification apparatus is capable of performing substitution or blood return by supplying the dialysate in the dialysate introduction line L1 to the blood circuit. In an ultrafiltration treatment in which the ultrafiltration pump is activated while the introduction of the dialysate into the dialyzer is stopped, dialysate delivery is performed while the introduction of the dialysate into the dialyzer is prevented.

A blood purification apparatus that is capable of, with no preparatory operations, performing substitution by supplying dialysate in a dialysate introduction line to a blood circuit during ultrafiltration treatment, or performing blood return by immediately supplying the dialysate in the dialysate introduction line to the blood circuit after the ultrafiltration treatment. A blood purification apparatus includes a dialyzer, a dialysate introduction line, a dialysate drain line L2 through which drain liquid from the dialyzer is drained, and an ultrafiltration pump capable of removing water from the blood in the blood circuit. The blood purification apparatus is capable of performing substitution or blood return by supplying the dialysate in the dialysate introduction line L1 to the blood circuit. In an ultrafiltration treatment in which the ultrafiltration pump is activated while the introduction of the dialysate into the dialyzer is stopped, dialysate delivery is performed while the introduction of the dialysate into the dialyzer is prevented.